Lantus – said to be the most administered ... The FDA approval was awarded to Mylan, which is now part of Viatris after merging with Pfizer's Upjohn division last year.

Lantus was a $6.5 billion product at its peak ... although delays to a second biosimilar from Mylan/Biocon applied the brake a little. Sales were €2.28 billion in the first nine months of ...